Researchers looked at how a group of medications called selective aldosterone synthase inhibitors (ASIs) affect people with chronic kidney disease (CKD) and uncontrolled high blood pressure. This analysis included data from 1,148 patients to see how these drugs performed compared to a placebo.
The findings showed that these medications were associated with a decrease in both systolic and diastolic blood pressure. Additionally, the study found a reduction in albuminuria, which is a sign of kidney damage. There was also a small decrease in the estimated glomerular filtration rate (eGFR) during the study period.
One important safety note is the risk of hyperkalemia, which is a high level of potassium in the blood. Because the data on this specific risk was inconsistent across different studies, it is hard to say exactly how common it is. While these drugs show promise for managing blood pressure and kidney health, they are still being evaluated for their role in standard care.
